newsfilter
← Latest News
GlobeNewswire·

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results

Obtained U.S. FDA IND clearance for ONCT-534, our dual-action androgen receptor inhibitor, for the treatment of patients with advanced prostate cancer who are resistant to approved androgen receptor signaling